Tracon gains on single patient study

Tracon Pharmaceuticals Inc. (NASDAQ:TCON) gained $4.23 (36%) to $15.96 after it said IV TRC105 generated a sustained complete response in a single-patient Phase II compassionate use study to treat choriocarcinoma. Results were presented at the World Congress on Gestational Trophoblastic Diseases in Indonesia.

Tracon said IV TRC105 in combination with Avastin bevacizumab normalized levels of beta-human chorionic gonadotropin (beta-hCG), a choriocarcinoma biomarker, after four cycles of treatment in a patient with previously treated metastatic choriocarcinoma. Tracon said the complete response was ongoing at 28 weeks. ...